PROK ProKidney Corp.
USHealthcareAs of 2026-07-09 16:00
Why PROK matters now
ProKidney Corp. (PROK) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.80 with -2.17% on the session and $605.3M in market capitalization; recent performance reads 1-month +18.06% and YTD -18.30%.
The latest financial table shown here is Q1 2026, with revenue of $226.0K, net income of $-22.6M, and EPS of $-0.16. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -24.4%.
The latest indexable market news headline is "ProKidney Appoints Kenneth Locke as Chief Technical Officer" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $5.00; recent insider activity includes Girolamo Todd C filing C-Conversion. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.25
P/S
692.18
EV/EBITDA
-3.44
DCF Value
$0.87
FCF Yield
-24.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
-224.4%
Operating Margin
-18959.7%
Net Margin
-8418.0%
ROE
7.4%
ROA
-25.6%
ROIC
-54.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $226.0K | $-22.6M | $-0.16 |
| Q4 2025 | $225.0K | $-19.2M | $-0.14 |
| FY 2025 | $893.0K | $-69.0M | $-0.52 |
| Q3 2025 | $217.0K | $-16.5M | $-0.12 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$4.67
Target (Median)
$5.00
Target Range
$3.00 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.70
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.